GTx and Tessera form prostate cancer test deal:
This article was originally published in Clinica
Executive Summary
In what could lead to a marriage of therapy and diagnostics for prostate cancer, biopharmaceutical firm GTx has linked up with Tessera to develop a blood or urine test for premalignant prostate lesions that can become cancerous. Under the agreement, Memphis, Tennessee-based GTx will provide clinical samples from its completed phase IIb clinical trial of its Acapodene (toremifene citrate) agent for reducing the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN). Tessera's early prostate cancer antigen, ProstaMark, will be used to identify patients with PIN lesions and/or early-stage prostate cancer.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.